The Pulmonary Fibrosis Biomarkers Market is gaining increased global attention as early detection and personalized treatment approaches for chronic lung diseases continue to evolve. Valued at US$ 4,290.43 million in 2024, the market is expected to grow at a CAGR of 4.50% from 2025 to 2032. With rising cases of pulmonary fibrosis and growing research into molecular-level disease indicators, the...